Martingale Asset Management L P Sells 1,300 Shares of ChemoCentryx, Inc. (NASDAQ:CCXI)
Martingale Asset Management L P Sells 1,300 Shares of ChemoCentryx, Inc. (NASDAQ:CCXI)
Martingale Asset Management L P trimmed its holdings in ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) by 7.4% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 16,334 shares of the biopharmaceutical company's stock after selling 1,300 shares during the quarter. Martingale Asset Management L P's holdings in ChemoCentryx were worth $410,000 at the end of the most recent reporting period.
根據最近提交給美國證券交易委員會的文件，Martingale Asset Management LP在第一季度將其在ChemoCentryx，Inc.(納斯達克代碼：CCXI-GET Rating)的持股削減了7.4%。該機構投資者在本季度出售了1,300股後，持有這家生物製藥公司的16,334股票。在最近一個報告期結束時，Martingale Asset Management L P在ChemoCentryx持有的股份價值410,000美元。
A number of other hedge funds have also bought and sold shares of CCXI. UMB Bank N A MO purchased a new stake in shares of ChemoCentryx during the 4th quarter valued at about $37,000. Lazard Asset Management LLC bought a new stake in ChemoCentryx in the 4th quarter worth approximately $60,000. Prospera Financial Services Inc bought a new stake in ChemoCentryx in the 1st quarter worth approximately $46,000. Point72 Hong Kong Ltd purchased a new stake in ChemoCentryx during the 4th quarter valued at $115,000. Finally, Commerce Bank bought a new position in shares of ChemoCentryx during the 4th quarter valued at $219,000. Hedge funds and other institutional investors own 81.09% of the company's stock.
其他一些對衝基金也買賣了CCXI的股票。UMB Bank N A MO在第四季度購買了ChemoCentryx的新股份，價值約3.7萬美元。Lazard Asset Management LLC在第四季度購買了ChemoCentryx的新股份，價值約6萬美元。普羅斯佩拉金融服務公司在第一季度購買了ChemoCentryx的新股份，價值約4.6萬美元。Point72 Hong Kong Ltd在第四季度購買了ChemoCentryx的新股份，價值11.5萬美元。最後，商業銀行在第四季度購買了價值21.9萬美元的ChemoCentryx股票的新頭寸。對衝基金和其他機構投資者持有該公司81.09%的股票。
Insider Activity
內幕活動
In related news, Director James L. Tyree sold 3,863 shares of the company's stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $25.66, for a total value of $99,124.58. Following the completion of the transaction, the director now owns 19,138 shares of the company's stock, valued at approximately $491,081.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director James L. Tyree sold 3,863 shares of the business's stock in a transaction dated Thursday, June 9th. The stock was sold at an average price of $25.66, for a total value of $99,124.58. Following the transaction, the director now directly owns 19,138 shares in the company, valued at $491,081.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas J. Schall sold 130,000 shares of the stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $50.24, for a total value of $6,531,200.00. Following the sale, the chief executive officer now owns 2,393,352 shares of the company's stock, valued at approximately $120,242,004.48. The disclosure for this sale can be found here. Insiders have sold 217,623 shares of company stock worth $10,848,962 in the last three months. Company insiders own 8.30% of the company's stock.
在相關新聞中，董事詹姆斯·L·泰裏在6月9日星期四的一次交易中出售了3,863股該公司股票。這些股票的平均價格為25.66美元，總價值為99,124.58美元。交易完成後，董事現在擁有19,138股該公司股票，價值約491,081.08美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過以下鏈接獲得。其他新聞方面，董事詹姆斯·L·泰裏在一筆日期為6月9日(星期四)的交易中出售了3,863股該公司股票。這隻股票的平均售價為25.66美元，總價值為99,124.58美元。交易完成後，董事現在直接擁有該公司19,138股，價值491,081.08美元。這筆交易是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份文件中披露的，可以通過這個超級鏈接獲得。此外，首席執行官託馬斯·J·沙爾在8月4日(星期四)的交易中出售了13萬股該公司股票。這隻股票的平均售價為50.24美元，總價值為6,531,200.00美元。出售後，首席執行官現在擁有2393,352股公司股票，價值約120,242,004.48美元。此次拍賣的披露信息可在此處找到。在過去的三個月裏，內部人士已經出售了217,623股公司股票，價值10,848,962美元。公司內部人士持有該公司8.30%的股份。
ChemoCentryx Price Performance
ChemoCentryx性價比
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several analysts recently commented on CCXI shares. SVB Leerink lowered ChemoCentryx from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $64.00 to $52.00 in a report on Friday, August 5th. StockNews.com upgraded shares of ChemoCentryx from a "sell" rating to a "hold" rating in a research note on Wednesday, August 10th. Stifel Nicolaus downgraded shares of ChemoCentryx from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th. Canaccord Genuity Group cut shares of ChemoCentryx from a "buy" rating to a "hold" rating and set a $52.00 target price for the company. in a report on Friday, August 5th. Finally, HC Wainwright cut shares of ChemoCentryx from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $101.00 to $52.00 in a research note on Friday, August 5th. Six investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, ChemoCentryx currently has a consensus rating of "Hold" and a consensus price target of $65.25.
幾位分析師最近對CCXI的股票發表了評論。SVB Leerink在8月5日星期五的一份報告中將ChemoCentryx的評級從“跑贏大盤”下調至“市場表現”，並將該股的目標價從64.00美元下調至52.00美元。在8月10日星期三的一份研究報告中，股票新聞網站將ChemoCentryx的股票評級從“賣出”上調為“持有”。Stifel Nicolaus在8月10日星期三的一份報告中將ChemoCentryx的股票評級從買入下調至持有。Canaccel Genuity Group將ChemoCentryx的股票評級從買入下調至持有，併為該公司設定了52.00美元的目標價。在8月5日星期五的一份報告中。最後，在週五的一份研究報告中，HC Wainwright將ChemoCentryx的股票評級從買入下調至中性，並將該股的目標價從101.00美元下調至52美元。六位投資分析師對該股的評級為持有，兩位給予買入評級，一位給予該公司強烈的買入評級。根據MarketBeat.com的數據，ChemoCentryx目前的共識評級為持有，共識目標價為65.25美元。
About ChemoCentryx
關於ChemoCentryx
(Get Rating)
(獲取評級)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
ChemoCentryx，Inc.是一家生物製藥公司，專注於在美國開發和商業化治療炎症性疾病、自身免疫性疾病和癌症的新藥。它提供TAVNEOS(Avacopan)，一種口服的選擇性C5aR抑制劑，用於治療嚴重的抗中性粒細胞胞漿自身抗體相關性小血管炎的成人患者。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- MarketBeat Podcast: Stock Market, Bad News is Good News
- Forget Bitcoin, Block's Ecosystems are the Real Growth Drivers
- What Does an Inverted Yield Curve Mean For You?
- SPY vs. QQQ: Which ETF Wins in 2022?
- Could Snap Stock Rebound As Management Restructures?
- 免費獲取StockNews.com關於ChemoCentryx(CCXI)的研究報告
- 市場Beat播客：股市，壞消息就是好消息
- 忘掉比特幣吧，Block的生態系統才是真正的增長動力
- 收益率曲線倒置對你意味着什麼？
- 標普500ETF VS QQQ：2022年哪隻ETF勝出？
- 隨着管理層重組，股市能否迅速反彈？
Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating).
想看看還有哪些對衝基金持有CCXI嗎？訪問HoldingsChannel.com獲取ChemoCentryx，Inc.(納斯達克代碼：CCXI-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.
接受ChemoCentryx日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ChemoCentryx和相關公司的最新新聞和分析師評級的每日簡要摘要。